European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
News
Enter now and showcase your talents industry-wide
The all new Sales Awards offers a unique opportunity for sales professionals at all levels of their career to sharpen their skills and showcase their talents industry-wide.
With just 6 weeks to go spaces are filling up fast – reserve your place now to avoid missing out
The PharmaTimes Marketer of the Year competition offers a unique opportunity for all marketers, from aspiring to experienced, to sharpen their skills and showcase their talents against marketing professionals, industry-wide.
Sobi launches Kineret for AOSD, SJIA
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
NICE backs AZ’ asthma biologic Fasenra
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
FDA approves first smallpox therapy
US regulators have approved the first treatment designed to mitigate the impact of a potential outbreak of smallpox caused by bioterrorism.
UCB, Amgen refile osteoporosis drug Evenity
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
Put your agency in the spotlight, ENTER NOW
“The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group’s Eric Hansen.
Recognising the outstanding achievements of medical and scientific professionals
PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events – and now is the time to enter!
Brexit ambition is ‘fine’ but execution is key, says Brexit Health Alliance
“There is always a danger that health issues are not kept to the fore” in negotiations, says Niall Dickson
NICE turns down Darzalex combo for pre-treated multiple myeloma
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
GSK sells psoriasis/dermatitis therapy to Dermavant
GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Zogenix’ drug cuts seizures in Dravet syndrome
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.
NHS under ‘intolerable’ strain
NHS Confederation chief executive Niall Dickson is warning that the NHS is “under intolerable strain”, after the latest performance data continue to show growing demand and missed targets.
Roche’s Venclexta filed in the US for acute myeloid leukemia
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
